Yolanda Gómez‐Gálvez

Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

Yolanda Gómez‐Gálvez, Cristina Palomo‐Garo, Javier Fernández‐Ruíz et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2015 · 213 citations

Medicine, Neuroscience, Pharmacology +14

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

Concepción García, María Gómez‐Cañas, Sonia Burgaz et al. · Journal of Neuroinflammation · 2018 · 64 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Targeting the cannabinoid CB 2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice

Cristina Palomo‐Garo, Yolanda Gómez‐Gálvez, Concepción García et al. · Pharmacological Research · 2016 · 53 citations

Life Sciences, Neuroscience, Pharmacology +15

Recovery after human bone marrow mesenchymal stem cells (hBM-MSCs)-derived extracellular vesicles (EVs) treatment in post-MCAO rats requires repeated handling

Yolanda Gómez‐Gálvez, Malvika Gupta, Mandeep Kaur et al. · PLoS ONE · 2024 · 10 citations · Full text

Medicine, Neurology, Neuroscience +17